

## A time course of hepcidin response to iron challenge in patients with HFE and TFR2 hemochromatosis

Domenico Girelli,<sup>1</sup> Paola Trombini,<sup>2</sup> Fabiana Busti,<sup>1</sup> Natascia Campostrini,<sup>1</sup> Marco Sandri,<sup>1</sup> Sara Pelucchi,<sup>2</sup> Mark Westerman,<sup>3</sup> Tomas Ganz,<sup>3,4</sup> Elizabeta Nemeth,<sup>3,4</sup> Alberto Piperno,<sup>2</sup> and Clara Camaschella<sup>5</sup>

<sup>1</sup>Department of Medicine, University of Verona, Verona, Italy; <sup>2</sup>Department of Clinical Medicine, Prevention and Biotechnologies, Milano Bicocca University, Milan, Italy; <sup>3</sup>Intrinsic LifeSciences, LLC, La Jolla, CA, USA; <sup>4</sup>Departments of Medicine and Pathology, David Geffen School of Medicine, University of California, Los Angeles, CA, USA; and <sup>5</sup>Vita-Salute University and Division of Genetics and Cell Biology San Raffaele Scientific Institute, Milan, Italy

Citation: Girelli D, Trombini P, Busti F, Campostrini N, Sandri M, Pelucchi S, Westerman M, Ganz T, Nemeth E, Piperno A, and Camaschella C. A time course of hepcidin response to iron challenge in patients with HFE and TFR2 hemochromatosis. Haematologica 2011;96(4):500-506. doi:10.3324/haematol.2010.033449

**Online Supplementary Table S1.** Results of the oral iron test (details). (A) Time-course of serum iron levels ( $\mu\text{g}/\text{dL}$ ). Median and interquartile range (in brackets) are shown for the five groups.

Time	0	4 h	8 h	12 h	24 h
Controls	113 (94 - 141)	146** (124 - 162)	98 (90 - 138)	89 (78 - 101)	108 (81 - 130)
C282Y/C282Y at diagnosis	163 (139 - 221)	217.5* (172 - 232)	189.5 (155 - 215)	171.5 (136 - 219)	183 (122 - 218)
C282Y/H63D at diagnosis	145 (89 - 156)	176.5* (139 - 207)	134.5 (120 - 149)	98 (90 - 118)	119 (115 - 173)
Iron-depleted patients	133 (127 - 161)	253** (236 - 281)	243** (217 - 269)	197* (175 - 213)	135 (116 - 143)
TFR2- patients	310 (270 - 350)	338 (298 - 378)	330.5 (283 - 378)	303 (256 - 350)	299.5 (219 - 380)

\* $P<0.05$  and \*\* $P<0.01$  as compared to basal at time 0.

(B) Time-course of transferrin saturation levels (%). Median with interquartile range (in brackets) are shown for the five groups.

Time	0	4 h	8 h	12 h	24 h
Controls	34 (30 - 41)	43* (35 - 47)	29 (26 - 39)	25* (21 - 29)	32 (24 - 40)
C282Y/C282Y at diagnosis	70.5 (46 - 83)	79.5 (54 - 86)	74.5 * (51 - 81)	63.5 (52 - 78)	63.5 (54 - 83)
C282Y/H63D at diagnosis	45 (37 - 57)	59.5 * (45 - 60)	43 (40 - 45)	31 (27 - 37)	41.5 (36 - 54)
Iron-depleted patients	48 (40 - 51)	82** (79 - 83)	77** (68 - 80)	66 * (53 - 68)	48 (27 - 49)
TFR2- patients	95 (93 - 97)	98.5 (98 - 99)	93 (92 - 94)	91 (88 - 94)	83.5 (70 - 97)

\* $P<0.05$  and \*\* $P<0.01$  as compared to basal at time 0.

(C) Time-course of serum hepcidin levels by ELISA (ng/mL). Median with interquartile range (in brackets) are shown for the five groups.

Time	0	4 h	8 h	12 h	24 h
Controls	59.6 (41.6 - 71.6)	92.2** (67.5 - 115.5)	100.6** (63.9 - 128.3)	103.6** (90.5 - 118.9)	49.8 (40.5 - 79.4)
C282Y/C282Y at diagnosis	41.9 (24 - 65.6)	44.2 (34.1 - 65.2)	54.7** (32.8 - 74.8)	58.7** (43 - 80.9)	48.3 (25.2 - 85.4)
C282Y/H63D at diagnosis	65.1 (50.8 - 71.1)	83.1* (77 - 103.5)	105.3 * (98.8 - 107)	107.1 (90.6 - 135.6)	69.7 (62.1 - 80.6)
Iron-depleted patients	9.6 (6.6 - 20)	11.4 (8.5 - 28.2)	13.9 (6.8 - 19)	29.1* (7.7 - 48.9)	10.9 (7 - 32.5)
TFR2- patients	1.8 (1 - 2.6)	4.6 (3.7 - 5.6)	6.1 (4.8 - 7.4)	5.2 (3.8 - 6.6)	9.2 (6.3 - 12)

\* $P<0.05$  and \*\* $P<0.01$  as compared to basal at time 0.

continued in the next page


continued from previous page

**Online Supplementary Table S1.** (D) Time-course of serum hepcidin levels measured by mass spectrometry (ng/mL). Median with interquartile range (in brackets) are shown for the five groups.


Time	0	4 h	8 h	12 h	24 h
Controls	10.3 (7 - 18)	22.1** (16 - 27.4)	27.6* (21.6 - 38.7)	34.4** (21.2 - 39)	11.7 (6.7 - 23.1)
C282Y/C282Y at diagnosis	12.2 (7.9 - 19.2)	21.8* (8.8 - 26.4)	20.7* (13.9 - 33.7)	18.8* (12.5 - 24.4)	16.8 (8 - 34.5)
C282Y/H63D at diagnosis	22.4 (13.1 - 35.4)	28 (23.7 - 34.3)	36 (18 - 45.1)	37.8* (27 - 63.8)	18.4 (7.3 - 18.7)
Iron-depleted patients	1.5 (1.5 - 1.5)	1.5 (1.5 - 8)	1.5 (1.5 - 7.7)	1.5* (1.5 - 17.3)	1.5 (1.5 - 1.5)
TfR2- patients	1.4 (1.4 - 1.4)	1.4 (1.4 - 1.4)	1.4 (1.4 - 1.4)	1.4 (1.4 - 1.4)	1.4 (1.4 - 1.4)

\*P<0.05 and \*\*P<0.01 as compared to basal at time 0.


A



B



**Online Supplementary Figure S1.** Box plots of square root areas under the curves (AUC) of serum iron (A) and transferrin saturation (B) in the five groups studied. C282Y homozygous and C282Y/H63D compound heterozygotes patients after iron depletion are grouped together. \*Significantly different from controls ( $P=0.0019$ ). Other significant differences: all patients at diagnosis versus all iron-depleted patients ( $P=0.0015$ ); C282Y homozygotes at diagnosis versus C282Y depleted patients ( $P=0.0014$ ); C282Y/H63D at diagnosis versus all iron-depleted patients ( $P=0.014$ ).



**Online Supplementary Figure S2.** Correlation between the two methods used to assay serum hepcidin. Total number of paired measures n=185.